Private equity buyers eye offer for GlaxoSmithKline's drinks brands

Private equity firms Blackstone and Lion Capital are together eyeing an offer for GlaxoSmithKline's ($GSK) drinks brands Lucozade and Ribena. Up for sale as the U.K.-based drugmaker sheds lower-performing and non-core assets, the brands could fetch a bid worth more than £1 billion. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.